Eric J. Small, MD

Stanford University, Stanford, CA, BS, 1980, Biology
Case Western Reserve University of Medicine, Cleveland, Ohio, MD, 1985, Medicine
Beth Israel Hospital, Boston, MA, Internship and Residency, 1988, Internal Medicine
University of California San Francisco, CA, Fellowship, 1991, Hematology/Oncology

• 1983-1983
  Research Fellow, Div. of Hematology/Oncology,Case Western ReserveUniversity, Cleveland, OH
• 1982-1983
  Pathology Fellowship, Department of Pathology, Case Western Reserve University, Cleveland, OH
• 1985-1988
  Internal Medicine Internship and Residency Training Program, Beth Israel Hospital, Boston, MA
• 1988-1989
  Clinical Fellow, Cancer Research Institute, University of California, San Francisco, CA
• 1989-1991
  Research Fellow, Cancer Research Institute, (Dr. Marc Shuman) University of California, San Francisco, CA
• 1991-1997
  Assistant Clinical Professor of Medicine, University of California, San Francisco, CA
• 1991-present
  Head, Urologic Medical Oncology Section, Division of Hematology/Oncology, Univ. of California, San Franciso
• 1996-present
  Co-Director, Urologic Oncology Program, University of California, San Francisco, CA
• 1997-2001
  Associate Clinical Professor of Medicine and Urology, University of California, San Francisco, CA
• 1999-present
  Chair, GenitoUrinary Committee, Cancer and Leukemia Group B (CALGB)
• 2001-present
  Clinical Professor of Medicine and Urology, University of California, San Francisco, CA
• 2007-present
  Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF, San Francisco, CA

• 1984
  Alpha Omega Alpha Honor Medical Society
• 1997
  Prostate Cancer Foundation Therapy Consortium

• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa M, Valone FH. Immunotherapy of hormone refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18:3894, 2000.
• Small EJ, Reese DM, Frohlich M, Bok R, Shinohara K, Grossfeld G, Kelly WK. A prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595, 2000.
• Reese DM, Fratesi P, Corry M, Novotny W, Small EJ. A phase II trial of humanizedanti-VEGF antibody for the treatment of androgen-independent prostate cancer. The Prostate Journal 3:2, 2001.
• Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, Eisenberger M. Serum PSA decline as a marker of clinical outcome in hormone refractory prostate cancer patients: Association with progression-free survival, pain endpoints and survival. J Clin Oncol 19:1304, 2001.
• Kantoff PW, Farmer DA, Halabi S, Hayes DF, Vogelzang NJ, Small EJ. Prognostic significance of reverse transcriptase polymerase chain reaction (rt-PCR) for prostate specific antigen in men with hormone refractory prostate cancer. J Clin Oncol 19:3025, 2001.
• Small EJ, Halabi S, Ratain M, Rosner G, Ansari R, Palchak D, Marshall E, et al. A phase III study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of CALGB 9480. J Clin Oncol 20:3369, 2002.
• Harris KA, Small EJ. Low-dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen-independent prostate cancer. J Urol 168:542, 2002.
• Rini BI, Weinberg V, Bok RA, Small EJ. PSA kinetics as a measure of the biologic effect of granulocyte-macrophage colony stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21:99, 2003.
• Small EJ, Smith MR, Seaman J, Kowalski M. A multicenter, randomized, placebo-controlled study of pamidronate disodium for the palliation of bone pain in patients with advanced prostate cancer. J Clin Oncol 21:4277, 2003.
• Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ. A phase II study of estramustine, docetaxel and carboplatin with G-CSF support in patients with hormone refractory prostate cancer: Cancer and Leukemia Group B 99813. Cancer 98:2592, 2003.
• Taplin ME, Halabi S, Wods B, Picus J, Hayes DF, Kantoff P, Vogelzang NJ, Small EJ. Androgen receptor mutations in androden independent prostate cancer: CALGB 9663. J Clin Oncol 21:2678, 2003.
• Halabi S, Small EJ, Kantoff PW, Dawson NA, Vogelzang NJ. A prognostic model for predicting overall survival in men with hormone refractory metastatic prostate cancer. J Clin Oncol 21:1232, 2003.
• Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. The prognostic significance of reverse transcriptase polymerase chain reaction (rt-PCR) for prostate specific antigen in prostate cancer patients with one prior hormonal therapy: A nested study within CALGB 9583. J Clin Oncol 21:490, 2003.
• Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, et al. A phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: Results of CALGB 9583. J.Clin Oncol 22:1025, 2004.
• Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola R, Small EJ. A prospective, multicenter, randomized phase II trial of the herbal supplement PC-SPES & diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 22:3707, 2004.
• Petrylak DP, Tangen CM, Hussain M, Lara PN, Jr., Jones JA, Small EJ, et al. Docetaxel and estramustine versus mitoxantrone and prednisone: Results of Southwest Oncology Group Intergroup Protocol 99-16. New Engl J Med 351:1513, 2004.
• Ryan CJ, Small EJ. Long-term response to ketoconazole as secondary hormonal therapy in prostate cancer. Am J Oncol Rev 3:471, 2004.
• Rini BI, Beinart G, Weinberg V, Small EJ. APC8015 (Provenge) in patients with androgen independent biochemically relapsed prostate cancer. Clin Prostate Cancer 4:55, 2005.
• Small EJ, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F, Jones L, Hershberg R. Results of a placebo-controlled phase III trial of immunologic therapy with Sipuleucel T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089, 2006.
• Halabi S, Vogelzang NJ, Ou SS, Small EJ. Survival of octagenarians with hormone refractory prostate cancer: A pooled analysis of eight Cancer & Leukemia Group B (CALGB) studies. J Urol 176:81, 2006.
• Rini B, Fong L, Weinberg V, Conry S, Small E. Combination immunotherapy with prostatic acid phosphotase-pulsed antigen presenting cells plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107:67, 2006.
• Wilding G, Soulie P, Trump D, Das-Gupta A, Small EJ. Results from a pilot trial of Geftinib (Iressa ZD19839) refractory prostate cancer. Cancer 106:1917, 2006.
• Rosenberg JE, Galsky MD, Weinberg VK, Oh WK, Kelly WK, Small EJ. A retrospective evaluation of second-line chemotherapy response in hormone refractory prostate cancer. Cancer 106:58, 2006.
• Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte macrophage colony-stimulating factor. J Urol 175: 2087, 2006.